Sandip M Prasad MD MPhil
Minimally Invasive Surgery, Stone Disease, Surgical Oncology
Director of Genitourinary Surgical Oncology, Morristown Medical Center Vice-Chair of Urology, Morristown Medical Center
Join to View Full Profile
261 James StreetSuite 2GMorristown, NJ 07960
Phone+1 973-539-0333
Dr. Prasad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sandip Prasad is an urologist in Morristown, NJ and is affiliated with Morristown Medical Center. He received his medical degree from Duke University School of Medicine and has been in practice 12 years. He specializes in minimally invasive surgery, stone disease, and surgical oncology and is experienced in prostate cancer, gynecologic oncology, urologic oncology, minimally invasive urologic surgery, and urologic trauma and reconstructive surgery.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 2006 - 2010- Brigham and Womens HospitalInternship, Transitional Year, 2005 - 2006
Duke University School of MedicineClass of 2005
University of CambridgeMphil, Epidemiology, With Distinction, 1998 - 1999
Harvard UniversityA.B., Environmental Science and Public Policy, Magna cum laude, 1994 - 1998
Certifications & Licensure
NJ State Medical License 2017 - 2027
SC State Medical License 2012 - 2017
IL State Medical License 2010 - 2014
MA State Medical License 2008 - 2010
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
Clinical Trials
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2013 Oct 14
Publications & Presentations
PubMed
- Reply by Authors.Sandip M Prasad, Dimitar Shishkov, Nikola V Mihaylov, Pencho Genov, Vasyl Terzi
The Journal of Urology. 2026-04-29 - UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.Sandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Pencho Genov, Vasyl Terzi
The Journal of Urology. 2026-03-25 - Urethrectomy with glans reconstruction and meatoplasty for rare high-grade urothelial carcinoma in distal urethra.Mahima Gurushankar, Meher Pandher, Courtney Berg, Sandip M Prasad, Amjad Alwaal
Urology Case Reports. 2026-01-01
Journal Articles
- Early discharge after laparoscopic or robotic partial nephrectomy: care pathway evaluationPatel A, Golan S, Razmaria A, Prasad S, Eggener S, Shalhav A, British Journal of Urology International, 1/1/2014
- Does robotic-assisted laparoscopic ileocystoplasty (RALI) reduce peritoneal adhesions compared to open surgeryRazmaria AA, Marchetti PE, Prasad SM, Shalhav AL, Gundeti MS, British Journal of Urology International, 1/1/2014
- Ultrasonography in prostate cancer: current roles and potential applications in radiorecurrent diseaseRosoff JS, Prasad SM, Savage SJ, World Journal of Urology, 1/1/2013
Press Mentions
Deion 'Coach Prime' Sanders Advocates for Bladder Cancer Screening After Close CallAugust 5th, 2025- FDA Approves Mitomycin Intravesical Solution for Non-Muscle Invasive Bladder CancerJune 13th, 2025
- UGN-102 May Be an Alternative to TURBT for Low Grade, Intermediate-Risk NMIBCApril 29th, 2025
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
